Flavane

Flavane

SCHEMBL14394530

c1ccc([C@@H]2CCc3ccccc3O2)cc1

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.51
ESR2 Q92731 2/20 0.51
KDM4E B2RXH2 1/20 0.51
ADORA3 P0DMS8 1/20 0.51
AR P10275 1/20 0.51
CYP19A1 P11511 1/20 0.51
MAOB P27338 1/20 0.51
HSD17B10 Q99714 1/20 0.51
SLC8A1 P32418 10/20 0.47
TSHR P16473 1/20 0.43
HTR1A P08908 1/20 0.43
ADRA2A P08913 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
FFAR1 O14842 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Flavane SCHEMBL27595228 1.00 ESR1 (0.51) ESR1ESR2KDM4EADORA3AR
Flavane SCHEMBL27889134 1.00 ESR1 (0.51) ESR1ESR2KDM4EADORA3AR
Flavane SCHEMBL29478071 1.00 ESR1 (0.51) ESR1ESR2KDM4EADORA3AR
Flavane SCHEMBL123287 1.00 ESR1 (0.51) ESR1ESR2KDM4EADORA3AR
Flavane SCHEMBL28787244 0.98 ESR1 (0.50) ESR1ESR2KDM4EADORA3AR
Flavane SCHEMBL28405195 0.98 ESR1 (0.50) ESR1ESR2KDM4EADORA3AR
Flavane SCHEMBL28394714 0.98 ESR1 (0.50) ESR1ESR2KDM4EADORA3AR
Flavane SCHEMBL28529260 0.98 ESR1 (0.50) ESR1ESR2KDM4EADORA3AR
Flavane SCHEMBL28823768 0.98 ESR1 (0.50) ESR1ESR2KDM4EADORA3AR
Flavane SCHEMBL26661841 0.98 ESR1 (0.54) ESR1ESR2KDM4EADORA3AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9980937-B2 Therapeutic agent for Alzheimer's disease NAGASAKI UNIVERSITY (JP) 2018-05-29 US disclosed
US-9980937-B2 Therapeutic agent for Alzheimer's disease NAGASAKI UNIVERSITY (JP) 2018-05-29 US disclosed
US-20170252318-A1 NOVEL THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE NAGASAKI UNIVERSITY (JP) 2017-09-07 US disclosed
US-20170252318-A1 NOVEL THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE NAGASAKI UNIVERSITY (JP) 2017-09-07 US disclosed
EP-1317437-B1 SYNTHESIS OF 4-ALPHA-ARYLEPICATECHINS MARS INC (US) 2007-10-03 EP disclosed
US-7268240-B2 Synthetic methods for polyphenols MARS, INC. 2007-09-11 US disclosed
US-20070197804-A1 Synthesis of 4alpha-arylepicatechins MARS, INCORPORATED 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170252318-A1 NOVEL THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE PSEN2, BACE1, PSEN1 ESR1 688/4885ESR2 322/4885KDM4E 3469/4885
US-20070197804-A1 Synthesis of 4alpha-arylepicatechins FABP7, FABP4, TEAD4 ESR1 896/4885ESR2 405/4885KDM4E 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.